These pharmacological intervention studies provide compelling evidence that the TGF‐β/SMAD2/3/STAT3 signaling pathway represents a critical upstream regulatory mechanism regulating C1R expression in GBM cells. This evidence concerns the gene TGFB1 and glioblastoma.